Research and Development Expense of CNBX Pharmaceuticals Inc. from 30 Nov 2013 to 30 Nov 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Summary
CNBX Pharmaceuticals Inc. quarterly and annual Research and Development Expense in USD history and change rate from 30 Nov 2013 to 30 Nov 2025.
  • CNBX Pharmaceuticals Inc. Research and Development Expense for the quarter ending 30 Nov 2025 was $0.
  • CNBX Pharmaceuticals Inc. Research and Development Expense for the twelve months ending 30 Nov 2025 was $0, a 100% decline year-over-year.
  • CNBX Pharmaceuticals Inc. annual Research and Development Expense for 2025 was $0, a 100% decline from 2024.
  • CNBX Pharmaceuticals Inc. annual Research and Development Expense for 2024 was $194,788, a 55% decline from 2023.
  • CNBX Pharmaceuticals Inc. annual Research and Development Expense for 2023 was $431,565, a 64% decline from 2022.
Source SEC data
View on sec.gov
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Change (%)
Research and Development Expense, Annual (USD)
Research and Development Expense, YoY Annual Change (%)

CNBX Pharmaceuticals Inc. Quarterly Research and Development Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $0 $0 $0 01 Sep 2025 30 Nov 2025 10-Q 14 Jan 2026 2026 Q1
Q3 2025 $0 $0 +$67,713 01 Jun 2025 31 Aug 2025 10-K 01 Dec 2025 2025 FY
Q2 2025 $67,713 $0 -$42,884 -100% 01 Mar 2025 31 May 2025 10-Q 14 Jul 2025 2025 Q3
Q1 2025 $24,829 $0 -$107,199 -100% 01 Dec 2024 28 Feb 2025 10-Q 14 Apr 2025 2025 Q2
Q4 2024 $82,370 $0 -$112,418 -100% 01 Sep 2024 30 Nov 2024 10-Q 14 Jan 2026 2026 Q1
Q3 2024 $194,788 $67,713 -$160,947 -173% 01 Jun 2024 31 Aug 2024 10-K 01 Dec 2025 2025 FY
Q2 2024 $355,735 $42,884 -$220,231 -84% 01 Mar 2024 31 May 2024 10-Q 14 Jul 2025 2025 Q3
Q1 2024 $575,966 $107,199 +$94,871 +770% 01 Dec 2023 29 Feb 2024 10-Q 14 Apr 2025 2025 Q2
Q4 2023 $481,095 $112,418 +$49,530 +79% 01 Sep 2023 30 Nov 2023 10-Q 13 Jan 2025 2025 Q1
Q3 2023 $431,565 $93,234 -$70,366 -43% 01 Jun 2023 31 Aug 2023 10-K 29 Nov 2024 2024 FY
Q2 2023 $501,931 $263,115 +$14,054 +5.6% 01 Mar 2023 31 May 2023 10-Q 15 Jul 2024 2025 Q3
Q1 2023 $487,877 $12,328 -$318,248 -96% 01 Dec 2022 28 Feb 2023 10-Q 16 Apr 2024 2024 Q2
Q4 2022 $806,125 $62,888 -$377,156 -86% 01 Sep 2022 30 Nov 2022 10-Q 12 Jan 2024 2024 Q1
Q3 2022 $1,183,281 $163,600 -$307,403 -65% 01 Jun 2022 31 Aug 2022 10-K 30 Nov 2023 2023 FY
Q2 2022 $1,490,684 $249,061 -$301,781 -55% 01 Mar 2022 31 May 2022 10-Q 14 Jul 2023 2023 Q3
Q1 2022 $1,792,465 $330,576 +$14,618 +4.6% 01 Dec 2021 28 Feb 2022 10-Q 14 Apr 2023 2023 Q2
Q4 2021 $1,777,847 $440,044 +$6,314 +1.5% 01 Sep 2021 30 Nov 2021 10-Q 13 Jan 2023 2023 Q1
Q3 2021 $1,771,533 $471,003 +$69,074 +17% 01 Jun 2021 31 Aug 2021 10-K 30 Nov 2022 2022 FY
Q2 2021 $1,702,459 $550,842 +$180,758 +49% 01 Mar 2021 31 May 2021 10-Q 14 Jul 2022 2022 Q3
Q1 2021 $1,521,701 $315,958 -$128,458 -29% 01 Dec 2020 28 Feb 2021 10-Q 12 Apr 2022 2022 Q2
Q4 2020 $1,650,159 $433,730 -$32,303 -6.9% 01 Sep 2020 30 Nov 2020 10-Q 13 Jan 2022 2022 Q1
Q3 2020 $1,682,462 $401,929 -$75,844 -16% 01 Jun 2020 31 Aug 2020 10-K 29 Nov 2021 2021 FY
Q2 2020 $1,758,306 $370,084 +$36,325 +11% 01 Mar 2020 31 May 2020 10-Q 14 Jul 2021 2021 Q3
Q1 2020 $1,721,981 $444,416 +$16,372 +3.8% 01 Dec 2019 29 Feb 2020 10-Q 14 Apr 2021 2021 Q2
Q4 2019 $1,705,609 $466,033 +$161,850 +53% 01 Sep 2019 30 Nov 2019 10-Q 14 Jan 2021 2021 Q1
Q3 2019 $1,543,759 $477,773 +$54,922 +13% 01 Jun 2019 31 Aug 2019 10-K 04 Nov 2020 2020 FY
Q2 2019 $1,488,837 $333,759 +$70,245 +27% 01 Mar 2019 31 May 2019 10-Q 14 Jul 2020 2020 Q3
Q1 2019 $1,418,592 $428,044 +$322,801 +307% 01 Dec 2018 28 Feb 2019 10-Q 13 Apr 2020 2020 Q2
Q4 2018 $1,095,791 $304,183 +$91,875 +43% 01 Sep 2018 30 Nov 2018 10-Q 14 Jan 2020 2020 Q1
Q3 2018 $1,003,916 $422,851 +$312,744 +284% 01 Jun 2018 31 Aug 2018 10-K 29 Nov 2019 2019 FY
Q2 2018 $691,172 $263,514 +$195,342 +287% 01 Mar 2018 31 May 2018 10-Q 15 Jul 2019 2019 Q3
Q1 2018 $495,830 $105,243 +$58,712 +126% 01 Dec 2017 28 Feb 2018 10-Q 15 Apr 2019 2019 Q2
Q4 2017 $437,118 $212,308 +$190,175 +859% 01 Sep 2017 30 Nov 2017 10-Q 17 Jan 2019 2019 Q1
Q3 2017 $246,943 $110,107 +$55,055 +100% 01 Jun 2017 31 Aug 2017 10-K 29 Nov 2018 2017 FY
Q2 2017 $191,888 $68,172 +$52,642 +339% 01 Mar 2017 31 May 2017 10-Q 16 Jul 2018 2018 Q3
Q1 2017 $139,246 $46,531 -$52,097 -53% 01 Dec 2016 28 Feb 2017 10-Q 05 Apr 2018 2018 Q2
Q4 2016 $191,343 $22,133 +$13,736 +164% 01 Sep 2016 30 Nov 2016 10-Q 16 Jan 2018 2018 Q1
Q3 2016 $177,607 $55,052 -$93 -0.17% 01 Jun 2016 31 Aug 2016 10-K 08 Dec 2017 2017 FY
Q2 2016 $177,700 $15,530 -$55,659 -78% 01 Mar 2016 31 May 2016 10-Q 17 Jul 2017 2017 Q3
Q1 2016 $233,359 $98,628 +$85,823 +670% 01 Dec 2015 29 Feb 2016 10-Q 14 Apr 2017 2017 Q2
Q4 2015 $147,536 $8,397 +$8,098 +2708% 01 Sep 2015 30 Nov 2015 10-Q 17 Jan 2017 2017 Q1
Q3 2015 $139,438 $55,145 +$55,145 01 Jun 2015 31 Aug 2015 10-K 13 Dec 2016 2016 FY
Q2 2015 $84,293 $71,189 +$71,189 01 Mar 2015 31 May 2015 10-Q 13 Jul 2016 2016 Q3
Q1 2015 $13,104 $12,805 +$12,805 01 Dec 2014 28 Feb 2015 10-Q 18 Apr 2016 2016 Q2
Q4 2014 $299 $299 +$299 01 Sep 2014 30 Nov 2014 10-Q/A 08 Apr 2016 2016 Q1
Q3 2014 $0 $0 01 Jun 2014 31 Aug 2014 10-K 07 Jan 2016 2015 FY
Q2 2014 $0 01 Mar 2014 31 May 2014 10-Q/A 17 Nov 2015 2015 Q3
Q1 2014 $0 01 Dec 2013 28 Feb 2014 10-Q/A 17 Nov 2015 2015 Q2
Q4 2013 $0 01 Sep 2013 30 Nov 2013 10-Q/A 17 Nov 2015 2015 Q1

CNBX Pharmaceuticals Inc. Annual Research and Development Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $0 -$194,788 -100% 01 Sep 2024 31 Aug 2025 10-K 01 Dec 2025 2025 FY
2024 $194,788 -$236,777 -55% 01 Sep 2023 31 Aug 2024 10-K 01 Dec 2025 2025 FY
2023 $431,565 -$751,716 -64% 01 Sep 2022 31 Aug 2023 10-K 29 Nov 2024 2024 FY
2022 $1,183,281 -$588,252 -33% 01 Sep 2021 31 Aug 2022 10-K 30 Nov 2023 2023 FY
2021 $1,771,533 +$89,071 +5.3% 01 Sep 2020 31 Aug 2021 10-K 30 Nov 2022 2022 FY
2020 $1,682,462 +$138,703 +9% 01 Sep 2019 31 Aug 2020 10-K 29 Nov 2021 2021 FY
2019 $1,543,759 +$539,843 +54% 01 Sep 2018 31 Aug 2019 10-K 04 Nov 2020 2020 FY
2018 $1,003,916 +$756,973 +307% 01 Sep 2017 31 Aug 2018 10-K 29 Nov 2019 2019 FY
2017 $246,943 +$69,336 +39% 01 Sep 2016 31 Aug 2017 10-K 29 Nov 2018 2017 FY
2016 $177,607 +$38,169 +27% 01 Sep 2015 31 Aug 2016 10-K 08 Dec 2017 2017 FY
2015 $139,438 +$139,438 01 Sep 2014 31 Aug 2015 10-K 13 Dec 2016 2016 FY
2014 $0 01 Sep 2013 31 Aug 2014 10-K 07 Jan 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.